Laia Agell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laia Agell has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Josep Lloreta
Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain
8 shared publications Silvia de Muga
Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain
8 shared publicationsNuria Juanpere
5 shared publicationsSergio Serrano
5 shared publicationsJosé A Lorente
Autonomous University of Barcelona, Barcelona, Spain
4 shared publicationsMarta Lorenzo
4 shared publications
Latest Publications
- Open Access
- 26 May 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (43) , 74106-74118
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
- 26 May 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (43) , 74106-74118
Open AccessERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
- 11 January 2013
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 12 (1) , 21-30
CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement
The TMPRSS2-ERG fusion has been reported in 42 to 78% of prostate tumors. More than 90% of ERG-overexpressing tumors harbor the fusion. The relationship between the TMPRSS2-ERG fusion and prognosis is controversial. Different studies have suggested a
- 11 January 2013
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 12 (1) , 21-30
CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement
The TMPRSS2-ERG fusion has been reported in 42 to 78% of prostate tumors. More than 90% of ERG-overexpressing tumors harbor the fusion. The relationship between the TMPRSS2-ERG fusion and prognosis is controversial. Different studies have suggested a
- 1 November 2012
- Published by Elsevier in The American Journal of Pathology
- Vol. 181 (5) , 1585-1594
A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer
- 1 November 2012
- Published by Elsevier in The American Journal of Pathology
- Vol. 181 (5) , 1585-1594
A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer
- 1 October 2012
- Published by Elsevier in Human Pathology
- Vol. 43 (10) , 1573-1582
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
- 1 October 2012
- Published by Elsevier in Human Pathology
- Vol. 43 (10) , 1573-1582
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
- 1 March 2011
- Published by Elsevier in Laboratory Investigation
- Vol. 24 (3) , 443-452
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
- 1 March 2011
- Published by Elsevier in Laboratory Investigation
- Vol. 24 (3) , 443-452
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
- Open Access
- 5 March 2010
- Published by Elsevier in Laboratory Investigation
- Vol. 23 (5) , 703-712
Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas
- 5 March 2010
- Published by Elsevier in Laboratory Investigation
- Vol. 23 (5) , 703-712
Open AccessMolecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas
- 1 June 2009
- Published by Elsevier in Laboratory Investigation
- Vol. 22 (6) , 848-856
FGFR3 mutations in prostate cancer: association with low-grade tumors
- 1 June 2009
- Published by Elsevier in Laboratory Investigation
- Vol. 22 (6) , 848-856
FGFR3 mutations in prostate cancer: association with low-grade tumors
- 1 December 2008
- Published by Elsevier in Laboratory Investigation
- Vol. 21 (12) , 1470-1478
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations
- 1 December 2008
- Published by Elsevier in Laboratory Investigation
- Vol. 21 (12) , 1470-1478
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations